Drugs / PPC-5650
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01818570 Comparator | Jan 2013 → Jan 2014 | gastroesophageal reflux disease | Asbjørn Mohr Drewes | Completed | No outcome recorded |
| Phase 1 | NCT01449487 Comparator | Jan 2012 → May 2013 | — | Aros Pharma ApS | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PPC-5650 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01449487 ↗ |
| Action | Inhibit | “It is a potent low molecular weight inhibitor for this class of ion channels” NCT01449487 ↗ |
| Modality | Small molecule | “PPC-5650 is a new chemical entity” NCT01449487 ↗ |
| Route | Other | “local administration in the rectum of PPC-5650” NCT01449487 ↗ |